Drugs / EDP-514
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04971512 | Aug → Dec 2021 | chronic hepatitis B virus infection | Enanta Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1 | NCT04783753 | Nov 2020 → Jun 2021 | hepatitis B virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04470388 | Sep 2020 → Aug 2021 | chronic hepatitis B virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04008004 | Jun 2019 → Jul 2021 | chronic hepatitis B virus infection | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-514 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04971512 ↗ |
| Route | Oral | “orally administered doses of EDP-514” NCT04008004 ↗ |